ASTRAZENECA PHARMA INDIA LIMITED AstraZeneca Pharma India Limited Stock NSE India S.E.
Equities
ASTRAZEN
INE203A01020
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,224 INR | -1.15% |
|
-1.57% | -5.47% |
| Sales 2022 | 8.06B 96.46M | Sales 2023 | 10.03B 120M | Capitalization | 81.18B 972M |
|---|---|---|---|---|---|
| Net income 2022 | 616M 7.38M | Net income 2023 | 993M 11.89M | EV / Sales 2022 | 7.38 x |
| Net cash position 2022 | 4.4B 52.66M | Net cash position 2023 | 4.93B 59.05M | EV / Sales 2023 | 7.6 x |
| P/E ratio 2022 |
104
x | P/E ratio 2023 |
81.8
x | Employees | - |
| Yield 2022 |
0.39% | Yield 2023 |
0.49% | Free-Float | 17.58% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.15% | ||
| 1 week | -1.57% | ||
| Current month | -1.96% | ||
| 1 month | +2.49% | ||
| 3 months | -17.26% | ||
| 6 months | +10.14% | ||
| Current year | -5.47% |
1 week
5 122.55
5 440.90
1 month
5 008.255 595.85
Current year
4 785.007 220.95
1 year
3 098.007 220.95
3 years
2 445.707 220.95
5 years
1 632.557 220.95
10 years
781.007 220.95
| Managers | Title | Age | Since |
|---|---|---|---|
Siva Padmanabhan
CEO | Chief Executive Officer | - | - |
Sanjeev Panchal
CEO | Chief Executive Officer | - | 03-01-31 |
Bhavana Agrawal
DFI | Director of Finance/CFO | - | 23-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Revathy Ashok
BRD | Director/Board Member | 65 | 16-12-01 |
| Chairman | 67 | 12-12-05 | |
| Director/Board Member | 50 | 21-12-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 5,224 | -1.15% | 13 097 |
| 24-04-16 | 5,285 | +1.64% | 5,299 |
| 24-04-15 | 5,200 | -2.03% | 25,650 |
| 24-04-12 | 5,308 | -1.68% | 5,214 |
| 24-04-10 | 5,398 | +0.77% | 20,691 |
Delayed Quote NSE India S.E., April 18, 2024 at 07:43 am EDT
More quotes
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Companyâs DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +28.51% | 676B | |
| +23.85% | 554B | |
| -8.27% | 349B | |
| +14.63% | 318B | |
| +6.45% | 291B | |
| +2.88% | 210B | |
| -0.46% | 204B | |
| -9.90% | 194B | |
| -11.83% | 144B |
- Stock Market
- Equities
- ASTRAZEN Stock
- ASTRAZEN Stock
